Skip to main
ASRT

ASRT Stock Forecast & Price Target

ASRT Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Assertio Holdings Inc. has demonstrated significant valuation potential through the Garda transaction, which offers substantial premiums to its stock prices and underscores the company's long-term market prospects. The strategic sale of non-Rolvedon assets to Cosette Pharmaceuticals indicates a focused operational approach and a commitment to enhancing its core offerings in oncology. Additionally, the reverse stock split mitigates delisting risks from NASDAQ, positioning Assertio more favorably in the marketplace and contributing to a more stable financial outlook.

Bears say

The analysis indicates a negative outlook for Assertio Holdings Inc., primarily due to several key risks that threaten its market position. Factors such as the inability to secure additional market share for ROLVEDON and Sympazan, high competition levels, and the potential loss of exclusivity for existing products contribute to these concerns. Additionally, the company faces significant financial strain highlighted by a substantial impairment of intangible assets and the presence of legacy products that have already lost market exclusivity, further undermining growth prospects.

ASRT has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assertio Therapeutics Inc (ASRT) Forecast

Analysts have given ASRT a Hold based on their latest research and market trends.

According to 2 analysts, ASRT has a Hold consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assertio Therapeutics Inc (ASRT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.